Insulet Archives - Page 2 of 9 - Medical Design Sourcing

Insulet applauds NICE guidance on hybrid closed loop insulin delivery

The Omnipod 5 hybrid closed-loop insulin delivery system worn on the back of an arm. [Image courtesy of Insulet]Insulet (Nasdaq: PODD) + supports new National Institute for Health and Care Excellence (NICE) guidance supporting automated insulin delivery for type 1 diabetes.

NICE published guidance recommending hybrid closed-loop systems for eligible people with type 1 diabetes in England and Wales.

Hybrid closed-loop systems, like the Insulet Omnipod 5, deliver insulin automatically based on calculations from glucose monitors. Medtronic, Tandem Diabetes Care and Beta Bionics also compete with Insulet in the automated insulin delivery space. Medtronic applauded automated insulin delivery recommendations from NICE last month.

NICE’s guidance, published this week, outlines that the systems require less input from the user, but manual insulin dosing is still needed sometimes, for example, around mealtimes. So, th…

Report: There’s still ‘mutual interest’ with EOFlow, Medtronic despite deal falling through

Business Korea reports that EOFlow CEO Kim Jae-jin is leaving the door open with regard to the company’s collapsed deal with Medtronic (NYSE: MDT) + .

Medtronic announced this week that it terminated its $738 million agreement to acquire EOFlow, a maker of insulin patch pumps. The medtech giant cited “multiple breaches” of terms in the agreement as the reason behind the decision.

According to the Business Korea report, Jae-jin said the company itself terminated the acquisition contract with Medtronic.

He said both sides tried to find a mutual agreement over the past few weeks, citing “fundamental differences in perspective.” The CEO said Medtronic views ongoing legal disputes over IP with patch pump leader Insulet as “uncertain.”

Get the full story at our sister site, Drug Delivery Business News.

Here’s what diabetes tech companies are doing on World Diabetes Day

Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day.

World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922.

In an effort to drive awareness and understanding of the chronic condition, a number of medtech companies in the diabetes space undertake efforts each year to celebrate and draw attention to the day and month recognizing the community. We compiled lists in 2021 and 2022 to share some of the initiatives brought forward by these companies.

On World Diabetes Day in 2023, here is what medtech’s diabetes community is doing:

Abbott

Abbott (NYSE:ABT) launched its new “Countdown at a Crossroads” initiative to mark National Diabetes Awareness Month.

The initiative features an animated installation promoting diabetes awareness at the Oculus Center…

Insulet stock soars on Q3 results, Dexcom G7 integration planned for early 2024

Insulet (Nasdaq: PODD) + shares got a boost from third-quarter results that came in ahead of the consensus forecast.

Shares of PODD were up more than 16% at $162.94 near the end of trading today — a day after the company released results after market close. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 2%.

Highlights for the quarter included FDA clearance for the Omnipod 5 app on Apple iOS and the limited launch of the Omnipod Go basal-only pump. Insulet also launched Omnipod 5 in Germany as it expects full European availability in 2024.

Perhaps the biggest news from Insulet’s third-quarter results was an update on a major integration development. The company said it’s on track to integrate Omnipod 5 with the Dexcom G7 by early 2024. Omnipod 5 already works with the Dexcom G6, while the company continues work on i…

Insulet launches National Diabetes Month initiatives

This marks the ninth straight year the company appears at the Nasdaq Stock Market. [Image from Insulet on LinkedIn in 2021]Insulet (Nasdaq:PODD) today announced a series of initiatives to recognize National Diabetes Awareness Month and World Diabetes Day.

The U.S. recognizes the month of November as National Diabetes Awareness Month, while World Diabetes Day falls on Nov. 14.

To recognize World Diabetes Day, Insulet’s team will appear at the Nasdaq Stock Market for the ninth consecutive year. Hollingshead and a group of global Insulet employees and customers will mark the day by ringing the Nasdaq’s closing bell. They also intend to speak about the importance of raising diabetes awareness, plus Insulet’s mission.

Earlier that day, Insulet plans for its employees to join the American Association of Nurse Practitioners (AANP) at NBC’s TODAY Show. This intends to recognize Nurse Practitioner Week and the role nurse practitioners play in diabe…

Insulet CFO departs for same post at 3M’s Health Care spinoff

Wayde McMillan. [Image from Insulet]Insulet (Nasdaq: PODD) + announced today that Wayde McMillan decided to leave his role as EVP, CFO and treasurer.

McMillan’s departure goes into effect on Oct. 20, 2023. He intends to join 3M as CFO of its Health Care business, which the company expects to spin off late this year or early next year.

President and CEO Jim Hollingshead called McMillan “a trusted partner and an excellent leader” of the company’s global finance team. He said McMillan helped to advance Insulet’s mission of improving the lives of people with diabetes.

“Wayde has helped make our company stronger and more resilient, ensuring we have the capabilities and financial strength to capitalize on the tremendous long-term growth opportunities Insulet is pursuing,” Hollingshead said in a news release. “On behalf of the board and our entire team, I thank Wayde for his…

Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies could be among those affected by the rise of the GLP-1 drug class. [Images courtesy of Insulet, Medtronic and Senseonics]Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry.

The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.

In addition to the popular therapeutics, some companies — like i20 Therapeutics and Vivani Medical — are developing long-term implants that elute GLP-1s.

Positive clinical results from these drugs led to some negative market movement for a few of the biggest names in diabetes technology. Analysts even recently trimmed some forecasts o…

Insulet fully launches Omnipod 5 in Germany, expects full European availability by end of 2024

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet (Nasdaq: PODD) + announced today that it commercially launched its Omnipod 5 automated insulin delivery system in Germany.

Acton, Massachusetts-based Insulet released the device for individuals aged two years and older with type 1 diabetes. Germany marks the third market for the latest-generation patch pump. The company launched Omnipod 5 in the U.S. in August 2022, then began its launch in the UK in June of this year. It received CE mark approval for children aged two and up in September 2022.

Get the full story at our sister site, Drug Delivery Business News.

Insulet raises 2023 guidance with Omnipod sales up 33%

Insulet (Nasdaq: PODD) + shares fell after hours today on second-quarter results that came in ahead of the consensus forecast.

Shares of PODD dipped 2.2% at $333 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 1.8%.

The Acton, Massachusetts-based automated insulin delivery technology maker posted profits of $27.3 million. That amounts to 39¢ per share on sales of $396.5 million for the three months ended June 30, 2023

Insulet recorded a massive bottom-line gain out of the red on sales growth of 32.4%.

Get the full story at our sister site, Drug Delivery Business News.

Find solutions to your most demanding medtech problem at DeviceTalks West

Add some essentials to your toolbox with engineering expertise from our upcoming show in California.

Intuitive President Dave Rosa will give a keynote interview at DeviceTalks West 2023. [Photo courtesy of Intuitive]

In the medical device industry, stubborn problems can cost millions in development expenses and delay the introduction of new life-saving tools and technologies.

That’s why we build our DeviceTalks meetings as a forum where successful medical device engineers, manufacturers and market-builders can share their best practices, providing solutions that help clear hurdles, speed product development and potentially save lives.

DeviceTalks attendees leave our meeting with notebooks full of critical advice and pockets full of business cards. We’ll help fill both at DeviceTalks West, which takes place Oct. 18-19 at the Santa Clara Convention Center in California. You can view the full agenda on our…

Report: Insulet prevails over Medtrum in France patent spat

Left: a diagram of the Insulet insulin pump patent in question. Top right: The Insulet Omnipod 5. Bottom right: The Medtrum TouchCare Nano.

According to a report in Europe, a Paris, France, court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent.

JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet.

In declaring the infringement, the court ordered Medtrum to recall its Nano TouchCare pumps sold in France. Patients already using the device received an exemption.

Get the full story at our sister site, Drug Delivery Business News.

8 drug delivery innovations you should know

Innovations in drug delivery never stop and, over the past 12 months or so, a wide variety have come under the spotlight.

Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing just how many ways we can deliver therapeutics.

About a year ago, we clued in readers to a list of six drug delivery innovations they should know. Here, we provide a couple of updates on those and try to introduce a few more developments that you should know:

The latest in automated insulin delivery tech

Automated insulin delivery represents one of the most high-profile markets in drug delivery, with the technology providing potentially life-saving therapy for people with diabetes.

The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]Last year’s roundup included the already FDA-cleared Omn…